Elite Pharmaceuticals Inc (ELTP)
0.6168
0.00 (0.00%)
USD |
OTCM |
Nov 22, 15:59
Elite Pharmaceuticals Enterprise Value: 657.76M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 657.76M |
| November 20, 2024 | 706.69M |
| November 19, 2024 | 718.97M |
| November 18, 2024 | 708.56M |
| November 15, 2024 | 597.72M |
| November 14, 2024 | 550.93M |
| November 13, 2024 | 612.25M |
| November 12, 2024 | 596.23M |
| November 11, 2024 | 575.82M |
| November 08, 2024 | 542.49M |
| November 07, 2024 | 531.92M |
| November 06, 2024 | 548.05M |
| November 05, 2024 | 542.49M |
| November 04, 2024 | 542.82M |
| November 01, 2024 | 533.47M |
| October 31, 2024 | 471.13M |
| October 30, 2024 | 462.59M |
| October 29, 2024 | 542.71M |
| October 28, 2024 | 605.74M |
| October 25, 2024 | 574.86M |
| October 24, 2024 | 612.67M |
| October 23, 2024 | 500.19M |
| October 22, 2024 | 638.85M |
| October 21, 2024 | 751.02M |
| October 18, 2024 | 622.83M |
| Date | Value |
|---|---|
| October 17, 2024 | 532.03M |
| October 16, 2024 | 516.00M |
| October 15, 2024 | 468.57M |
| October 14, 2024 | 444.43M |
| October 11, 2024 | 462.27M |
| October 10, 2024 | 432.04M |
| October 09, 2024 | 425.09M |
| October 08, 2024 | 428.72M |
| October 07, 2024 | 423.60M |
| October 04, 2024 | 416.33M |
| October 03, 2024 | 414.62M |
| October 02, 2024 | 446.30M |
| October 01, 2024 | 412.27M |
| September 30, 2024 | 412.38M |
| September 27, 2024 | 415.89M |
| September 26, 2024 | 414.77M |
| September 25, 2024 | 413.76M |
| September 24, 2024 | 403.72M |
| September 23, 2024 | 399.28M |
| September 20, 2024 | 397.71M |
| September 19, 2024 | 414.72M |
| September 18, 2024 | 413.22M |
| September 17, 2024 | 407.90M |
| September 16, 2024 | 415.68M |
| September 13, 2024 | 383.95M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
25.44M
Minimum
Mar 31 2023
751.02M
Maximum
Oct 21 2024
92.89M
Average
57.39M
Median
May 12 2021
Enterprise Value Benchmarks
| Biomarin Pharmaceutical Inc | 11.76B |
| BioCardia Inc | 4.858M |
| Zevra Therapeutics Inc | 456.85M |
| Verrica Pharmaceuticals Inc | 65.49M |
| Terns Pharmaceuticals Inc | 112.22M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.04M |
| Revenue (Quarterly) | 18.88M |
| Total Expenses (Quarterly) | 15.40M |
| EPS Diluted (Quarterly) | -0.01 |
| Gross Profit Margin (Quarterly) | 43.42% |
| Profit Margin (Quarterly) | -58.45% |
| Earnings Yield | -1.42% |
| Operating Earnings Yield | 2.25% |
| Normalized Earnings Yield | 0.5857 |